Physician profile
Steven Gulevich
NPI 1437121613
$15,199.16
in general payments reported to CMS, 2019-2025
62 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,131 · 2020: $2,312 · 2021: $3,246 · 2022: $3,276 · 2023: $3,126 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Travel and Lodging: $733 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.17 |
| Travel and Lodging | $732.68 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,162.41 | 2019-2023 | Tysabri, Vumerity |
| Genzyme Corporation | $896.97 | 2019-2023 | |
| US Oncology Corporate, INC. | $893.66 | 2023 | |
| Amgen INC. | $840.09 | 2019-2023 | Aimovig |
| Abbvie INC. | $716.18 | 2021-2023 | |
| Emd Serono, INC. | $642.11 | 2019-2023 | Mavenclad |
| Ucb, INC. | $610.38 | 2019-2023 | Nayzilam |
| Neurocrine Biosciences, INC. | $577.01 | 2019-2023 | Ingrezza, Ongentys |
| Allergan, INC. | $562.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $532.08 | 2019-2023 | |
| Celgene Corporation | $492.98 | 2020-2023 | Zeposia |
| Genentech USA, INC. | $390.66 | 2019-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $371.10 | 2019-2023 | Ultomiris |
| Lundbeck LLC | $360.81 | 2020-2023 | Vyepti, Rexulti |
| Livanova USA, INC. | $347.40 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gulevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.